Abstract
Peptide-based cancer vaccines offer high antigen specificity but are frequently limited by rapid degradation, inefficient delivery, and insufficient immune priming, particularly due to tumor antigen heterogeneity. To address these challenges, we developed a biomimetic liposomal nanovaccine that integrates defined HER2-derived peptide epitopes with native tumor antigens through cancer cell membrane (CCM) functionalization. A HER2-derived multi-epitope peptide comprising cytotoxic T-lymphocyte and B-cell epitopes, conjugated to keyhole limpet hemocyanin (KLH), was encapsulated within liposomes, followed by surface coating with CCM to reconstruct a tumor-mimetic nano–bio interface for enhanced immune recognition. The nanovaccine formulation was optimized for peptide encapsulation efficiency, membrane coating integrity, and particle size distribution. In vivo immunization studies in BALB/c mice demonstrated that CCM-coated liposomal nanovaccines elicited significantly enhanced HER2-specific humoral and cellular immune responses, including elevated IgG titers, increased splenocyte proliferation, and augmented IFN-γ secretion, without inducing reactogenicity or excessive inflammatory responses. Importantly, prophylactic efficacy was strongly influenced by the source of the CCM, with antigen-matched membranes producing superior tumor growth suppression and prolonged survival compared with mismatched membrane coatings in a HER2-positive breast cancer challenge model. Overall, this study demonstrates that rational integration of well-defined HER2 peptide epitopes with homologous CCM antigens within a single liposomal delivery system can substantially enhance immune priming and prophylactic efficacy. These findings highlight the critical role of membrane source selection in biomimetic nanovaccine design and provide a conceptual avenue toward personalized cancer vaccination, wherein CCM may be sourced from individual tumors to tailor antigenic presentation.